Cohance Lifesciences Ltd

  • BSE Code : 543064
  • NSE Symbol : COHANCE
  • ISIN : INE03QK01018
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 311.95 10.50(3.48%)

Open Price ()

308.95

Prev. Close ()

301.45

Volume (No’s)

497,644

Market Cap ()

11,934.18

Low Price ()

304.00

High Price ()

317.50

 

Corporate Announcement

27-Mar-2026 Cohance Lifesciences Limited - Trading Window
20-Feb-2026 Cohance Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates
13-Feb-2026 Cohance Lifesciences Limited - Copy of Newspaper Publication
12-Feb-2026 Cohance Lifesciences Limited - Investor Presentation
22-Jan-2026 Cohance Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Stock Summary

Market Cap(₹Cr.)

11,549.70

P/E (TTM)

34.15

Book value ()

115.25

Div Yield (%)

0

EPS (TTM)

8.84

Face Value ()

1.00

Technical Analysis

Key Level

Resistance 1

305.92

Resistance 2

310.38

Support 1

295.57

Support 2

289.68

Moving Average

30 Days

302.16

50 Days

331.37

100 Days

445.43

200 Days

694.28

Peers Group

Company Market Cap (₹in Cr.) P/E (x) P/B(x) EV / EBITDA(x) Dividend Yield(%) EPS
Cohance Lifesciences Ltd 11,918.88 35.24 12.75 416.55 0 8.84
Sun Pharmaceutical Indust.. 414,713.05 95.02 17.11 7162.05 0.93 18.19
Divis Laboratories Ltd 156,810.96 60.95 10.27 3332 0.51 96.91
Torrent Pharmaceuticals L.. 139,052.00 62.26 14.42 3583.06 0.15 65.99
Lupin Ltd 103,944.24 18.8 3.81 5569.31 0.53 120.95

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made investment of Returns(%)

in Months Ago

My investment would be worth with a Loss of

Share Holding

CATEGORY NO. OF SHARES PERCENTAGE (%)
Total Foreign 25210644 6.59
Total Institutions 82504075 21.57
Total Govt Holding 37834 0.01
Total Non Promoter Corporate Holding 27831233 7.28
Total Promoters 219930170 57.49
Total Public & others 27053184 7.07
Total 382567140 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

Corporate Actions

About Company

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018. The name of the Company has been changed to Cohance Lifesciences Limited w.e.f. May 7, 2025. Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations.

Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Co...

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew